Metavia INC Form 4 insider transactions

Director James Tursi was granted 17,186 restricted stock units under MetaVia Inc.'s 2022 Equity Incentive Plan.

Director D. Gordon Strickland was granted 17,186 restricted stock units in MetaVia Inc. as part of the company's 2022 Equity Incentive Plan.

Director Michael Salsbury was granted 17,186 restricted stock units under the MetaVia Inc. 2022 Equity Incentive Plan.

Director Jason L. Groves was granted 17,186 restricted stock units under MetaVia Inc.'s 2022 Equity Incentive Plan.

Director Andrew Koven was granted 17,186 restricted stock units under MetaVia Inc.'s 2022 Equity Incentive Plan.

Director Mark A. Glickman was granted 17,186 restricted stock units in MetaVia Inc. as part of the company's 2022 Equity Incentive Plan.

MetaVia Inc.'s CFO, Marshall H. Woodworth, received 28,000 restricted stock units, with his beneficial ownership adjusted for a recent 1-for-11 reverse stock split.

MetaVia Inc.'s CEO and President, Hyung Heon Kim, was granted 32,000 restricted stock units under the company's equity incentive plan.

MetaVia Inc.'s CFO, Marshall H. Woodworth, reported gifting 14,200 shares of common stock and updated his power of attorney for SEC filings.

MetaVia Inc. Director Mark A. Glickman was granted 28,147 restricted stock units (RSUs) under the company's 2022 Equity Incentive Plan, increasing his beneficial ownership to 37,887 shares.

MetaVia Inc. Director Jason L. Groves was granted 28,147 restricted stock units, vesting in 2026, as part of the company's equity incentive plan.

MetaVia Inc. Director James Patrick Tursi was granted 28,147 restricted stock units under the company's 2022 Equity Incentive Plan, increasing his direct beneficial ownership to 37,219 shares.

MetaVia Inc. Director D. Gordon Strickland was granted 28,147 restricted stock units, increasing his beneficial ownership to 45,699 shares.

MetaVia Inc. Director and 10% Owner Andrew I. Koven was granted 28,147 restricted stock units, increasing his direct beneficial ownership to 45,699 shares, and formalized a Power of Attorney for regulatory compliance.

MetaVia Inc. Director Michael Salsbury was granted 28,147 restricted stock units, which will vest by June 30, 2026, with receipt deferred until a change in control or separation from service.

MetaVia Inc.'s Chief Financial Officer, Marshall H. Woodworth, has increased his direct ownership in the company by purchasing 14,200 shares of common stock.

DONG-A ST CO., LTD acquired 4,647,887 shares of MetaVia Inc. at $0.71 per share, increasing its total holdings to 9,995,679 shares.

Marshall H. Woodworth, CFO of MetaVia Inc., disposed of 3,417 shares of common stock to cover tax liabilities related to vesting restricted stock units.

CEO Kim Hyung Heon of MetaVia Inc. reports disposition of shares to cover tax obligations related to vesting restricted stock units.

MetaVia Inc.'s CEO, Hyung Heon Kim, sold 2,867 shares of common stock to cover tax liabilities related to vesting restricted stock units.

Dong-A ST Co., Ltd., a significant shareholder in NeuroBo Pharmaceuticals, acquired warrants to purchase common stock following stockholder approval.

CEO Kim Hyung Heon of NeuroBo Pharmaceuticals reports disposition of shares to cover tax obligations related to vesting restricted stock units.

Dong-A ST Co., Ltd. files an amended SEC Form 4 to correct a previously reported share price for a transaction involving NeuroBo Pharmaceuticals (NRBO) common stock.

Dong-A ST Co., Ltd. reports acquiring shares of NeuroBo Pharmaceuticals, Inc. at $3.13 per share.

Director Michael Salsbury received a grant of restricted stock units and adjusted his holdings to reflect a reverse stock split.

Director Jason L. Groves receives a grant of restricted stock units and reports changes in beneficial ownership of NeuroBo Pharmaceuticals stock.

Director Andrew Koven reports the acquisition of 5,051 restricted stock units and an adjustment to previously held securities due to a reverse stock split.

Mark A. Glickman, a director of NeuroBo Pharmaceuticals, reported the acquisition of 5,051 shares of common stock and the disposal of 9,740 shares on June 7, 2024.

D Gordon Strickland, a director of NeuroBo Pharmaceuticals, reported the acquisition of 5,051 common stock shares and disposal of 0 shares on June 7, 2024.

Director James Patrick Tursi reports acquisition and disposal of NeuroBo Pharmaceuticals common stock and restricted stock units.